Discover the 2017 agenda

TRACK 1 – NEW PLAYERS INVOLVED IN INNOVATION IN THE HEALTH SECTOR

TRACK 2 – NURTURING AND LICENSING EARLY-STAGE ASSETS

TRACK 3 – BIOENTREPRENEURS’ CHALLENGES AT PRE-SEED, SEED AND SERIES A STAGES


DAY ONE – 28th Nov. 2017

Conferences and roundtable discussions

Presentation sessions

Hosted event

Partnering

8.30am
9.30am

WELCOME COFFEE

LM 3

COFFEE

9.30am
11.00am

Shared risk or competition for emerging assets: How can we optimise pharma-VC relationships?

How can collaborations in rare diseases be an asset in a highly competitive and fast moving market?

Licensing Opportunity Presentations

Cancerology
Osteo-Articular

Translational research at Medalis: From lab to biotech

Biofit-01

One-to-one meetings
&

SIMV

R&D dating for animal health and innovation

11.00am
11.30am

NETWORKING BREAK

11.30am
1.00pm

PLENARY SESSION

How can we overcome the shortage
of bioentrepreneurs in Europe?

1.00pm
2.30pm

LUNCH

2.30pm
4.00pm

Exploring the growing relationship between pharma, digital health companies and data providers

Assessing the opportunity for licensing early-stage projects

Start-up Slams

Vascular / Metabolic
Op2Lysis, Emosis, Cardior Pharmaceuticals, AptamiR Therapeutics

Vaccinology / Virology
ViRelieve, Vaxinano, Par’Immune

Early projects, early opportunity: Find your match

Biofit-01

One-to-one meetings

4.00pm
4.30pm

NETWORKING BREAK

&

4.30pm
6.00pm

How are focused therapeutic funds becoming increasingly important at pre-seed, seed and Series A stages?

Workshop: A closer look at early-stage collaborations in the UK

Licensing Opportunity Presentations

Cancerology
Osteo-Articular

Nature and nurture of an Academic drug discovery Centre

SIMV

R&D dating for animal health and innovation

6.30pm

BIOPARTY


DAY TWO – 29th Nov. 2017

Conferences and roundtable discussions

Presentation sessions

Partnering

8.30am
9.00am

WELCOME COFFEE

9.00am
10.30am

How to keep the founding scientists committed?

How are collaborations key to improve innovation in metabolic diseases?

Start-up Slams

Oncology / Immuno-onco
STipe Therapeutics, Theranovir, Elthera, ChromaLys

10.30am
11.00am

NETWORKING BREAK

11.00am
12.30pm

Where will European
pre-seed, seed and Series A investment go in 2018?

How can animal and human innovation / applications be mutually beneficial?

Licensing Opportunity Presentations

Neurology
Vascular / Metabolic

Biofit-01

One-to-one meetings

12.30pm
2.00pm

LUNCH

&

2.00pm
3.30pm

Are venture philanthropy and trusts emerging in the initial stages of funding?

How can TTOs increase their role in the early development of spin-offs?

Start-up Slams

Research tools / Therapeutic delivery
Mecachips, DyNAbind, SimplicityBio, Renovos
Ageing / Pain
Innopain, PRAGMA Therapeutics, Reminisciences

SIMV

R&D dating for animal health and innovation

3.30pm
4.00pm


How can we define a mutually beneficial collaboration between an academic institution and a resulting spin-off?

Award ceremony of the most innovative start-up

4.00pm
4.30pm

4.30pm
5.00pm

CLOSING COFFEE BREAK

5.00pm
6.00pm

Arriving in Strasbourg on 27th November?

6.00 – 7.00pm: Free guided visit around the old city of Strasbourg
From 7.00pm onwards: Taste Alsatian specialties
And if you’re hungry after these tastings, book your dinner in a selection of typical restaurants and benefit from BioFIT offers!

For more information, look at the Welcome Evening page.